Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
AbstractAs evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies. Supported by rapid advances in antibody engineering and the development of several technological platforms such as Triomab or bispecific T cell engagers (BiTEs), the “bispecifics” market has increased significantly over the past decade and may occupy a pivotal space in the future. Over 30 bispecific molecules are currently in different stages of clinical trials and more than 70 in preclinical phase. This review focuses on the clinical potential of bispecific antibodies as immune effector cell engagers in the onco-immunotherapy field. We summarize current strategies targeting various immune cells and their clinical interests. Furthermore, perspectives of bispecific antibodies in future clinical developments are addressed. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Del Bano, J.; Chames, P.; Baty, D.; Kerfelec, B. Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward? Antibodies 2016, 5, 1.
Del Bano J, Chames P, Baty D, Kerfelec B. Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward? Antibodies. 2016; 5(1):1.Chicago/Turabian Style
Del Bano, Joanie; Chames, Patrick; Baty, Daniel; Kerfelec, Brigitte. 2016. "Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?" Antibodies 5, no. 1: 1.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.